EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Senolytics in Osteoporosis

Erman Chen iD, Jingjing Zhang, Han Chen, Weixu Li

Biomolecules · 16.08.2025 · 15 (8) · 1176

DOI: 10.3390/biom15081176 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 16.08.2025. Verfasst von Erman Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310014, China. Hauptthemen laut MEDLINE: Osteoporosis, Senotherapeutics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cellular senescence is a fundamental contributor to numerous dysfunctions and degenerative diseases, including osteoporosis. In genetically modified and preclinical animal models, therapeutic strategies targeting persistent senescent cells have been shown to delay and prevent osteoporosis. Senolytics are a class of drugs or compounds designed to selectively eliminate senescent cells without adversely affecting normal cells. In this review, we focus on the role of senolytic agents in regulating bone metabolism and their potential in the treatment of osteoporosis. We discussed major types of senolytics, such as natural compounds, kinase inhibitors, Bcl-2 family inhibitors, inhibitors of the mouse double minute 2/p53 interaction, heat shock protein 90 inhibitors, p53-binding inhibitors, and histone deacetylase inhibitors. This review also highlights the progress of senolytics in clinical trials. However, clinical results diverge from preclinical evidence. Therefore, senolytics should be critically evaluated as a potential therapeutic strategy for osteoporosis, with further validation required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisSenotherapeuticsHumansAnimalsCellular Senescence

Stichwörter der Autor:innen

cell senescenceclinical trialsflavonoidosteoporosissenolytics

Substanzen

Senotherapeutics

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310014, China.
  • Orthopedics Research Institute, Zhejiang University, Hangzhou 310027, China.
  • Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou 310009, China.
  • Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou 310009, China.
  • School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.

ORCID-Profile: Erman Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, E., Zhang, J., Chen, H., & Li, W. (2025). The Role of Senolytics in Osteoporosis. Biomolecules, 15(8), 1176. https://doi.org/10.3390/biom15081176

Vancouver

Chen E, Zhang J, Chen H, Li W. The Role of Senolytics in Osteoporosis. Biomolecules. 2025;15(8):1176. doi:10.3390/biom15081176

BibTeX
@article{Chen2025,
  author = {Chen, Erman and Zhang, Jingjing and Chen, Han and Li, Weixu},
  title = {The Role of Senolytics in Osteoporosis},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {8},
  pages = {1176},
  doi = {10.3390/biom15081176}
}
Kostenlos starten →